Oluyemi Okupe Sells 85,000 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Key Points

• CFO Oluyemi Okupe sold 85,000 shares of Hims & Hers Health for $5,117,000, reducing his ownership by 54.76% to 70,232 shares.
• Shares of Hims & Hers Health have decreased by 4.1%, trading at $56.71, with a significant average trading volume compared to the previous day.
• Several analysts have downgraded Hims & Hers Health, with the average target price set at $38.92 and a general rating of "Reduce" reflecting mixed market sentiment.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 85,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $60.20, for a total value of $5,117,000.00. Following the transaction, the chief financial officer owned 70,232 shares in the company, valued at $4,227,966.40. The trade was a 54.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, September 22nd, Oluyemi Okupe sold 23,584 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.74, for a total value of $1,361,740.16.
• On Monday, September 15th, Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $55.35, for a total value of $8,025,750.00.
• On Tuesday, August 26th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $43.69, for a total value of $505,973.89.
• On Monday, July 14th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $47.70, for a total value of $552,413.70.
• On Monday, July 7th, Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock. The stock was sold at an average price of $46.67, for a total value of $540,485.27.

Hims & Hers Health Stock Down 4.1%

Shares of HIMS traded down $2.41 during trading hours on Tuesday, reaching $56.71. The stock had a trading volume of 20,717,295 shares, compared to its average volume of 32,827,969. Hims & Hers Health, Inc. has a 12 month low of $16.05 and a 12 month high of $72.98. The firm has a 50-day simple moving average of $51.45 and a 200 day simple moving average of $46.72. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The company has a market capitalization of $12.82 billion, a price-to-earnings ratio of 70.89, a P/E/G ratio of 3.94 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. Hims & Hers Health's revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on HIMS. Needham & Company LLC restated a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a research report on Monday, July 28th. Finally, Zacks Research lowered Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average target price of $38.92.

Institutional Investors Weigh In On Hims & Hers Health

Several large investors have recently added to or reduced their stakes in the company. Corient Private Wealth LLC grew its holdings in Hims & Hers Health by 63.0% during the 2nd quarter. Corient Private Wealth LLC now owns 18,148 shares of the company's stock valued at $905,000 after buying an additional 7,016 shares in the last quarter. Texas Permanent School Fund Corp purchased a new position in Hims & Hers Health during the 2nd quarter valued at about $2,569,000. Centaurus Financial Inc. purchased a new position in Hims & Hers Health during the 2nd quarter valued at about $171,000. Thrivent Financial for Lutherans grew its holdings in Hims & Hers Health by 3.6% during the 2nd quarter. Thrivent Financial for Lutherans now owns 46,444 shares of the company's stock valued at $2,315,000 after buying an additional 1,617 shares in the last quarter. Finally, Marex Group plc purchased a new position in Hims & Hers Health during the 2nd quarter valued at about $53,626,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.